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Atopicdermatitiscanbeduetoavarietyofcausesfromnonatopictriggerstofoodallergy.Controlofegressofwaterandprotection
fromingressofirritantsandallergensarekeycomponentsofcutaneousbarrierfunction.Currentresearchsuggeststhatadegraded
barrier function of the skin allows the immune system inappropriate access to environmental allergens. Epidermal aeroallergen
exposure may allow sensitization to allergen possibly initiating the atopic march. Further research into connections between
epidermal barrier function and possible allergen sensitization will be important to undertake. Future clinical trials focused on
skin barrier protection may be of value as a possible intervention in prevention of the initiation of the atopic march.
1.Introduction
T h ea t o p i cm a r c hr e f e r st ot h en a t u r a lp r o g r e s s i o no f
atopic diseases from atopic dermatitis in infancy to atopic
asthmainschoolagechildren.Recentresearchhasuncovered
exciting data concerning the initiation of the atopic march.
A previously little valued component of the epidermis,
the strateum corneum, has become an area of scientiﬁc
attention in the study of the allergic diathesis. This focus on
epidermal barrier function potentially provides a heightened
understanding of both atopic dermatitis and the initiation of
the atopic march. Improving barrier function with reduced
water loss and minimized ingress of allergens might become
an important tool to controlling the onset of the atopic
march.
2. Epidemiology and Deﬁnition of
AtopicDermatitis
Atopic dermatitis is one of the most signiﬁcant and common
skin diseases of childhood. Studies from Japan suggest that
the prevalence for atopic dermatitis in childhood may be as
high as 11–25% [1, 2]. There is a 15.8% prevalence of atopic
dermatitis in 3–5-year-old children in New Zealand [3]. A
US-population-based study revealed that the prevalence of
atopic dermatitis amongst 5–9-year olds was 17.2% [4, 5].
Atopic dermatitis is an inﬂammatory cutaneous disease
characterizedbyerythema,pruritus,alteredbarrierfunction,
and immune dysfunction resulting in IgE sensitization.
Dysfunction of antimicrobial peptides such as defensins,
psoriasins, and cathelicidins is associated with the devel-
opment of atopic dermatitis [6–8]. Functional alteration of
these peptides has been associated with eczema herpeticum.
A perturbation in the function of these peptides can result
in cutaneous infection with Staphylococcus aureus.I n f e c t i o u s
sequelae frequently result in atopic dermatitis exacerbations.
These and other developments in atopic dermatitis are
exciting. However, the emphasis of this paper will be
conﬁned to deﬁning the importance of altered strateum
corneum function and its possible link to the atopic march.
3. Components of the Strateum Corneum
EstablishingSkinBarrierFunction
Epidermal layers of the skin include, the stratum corneum,
stratum lucidum, stratum granulosum, stratum spinosum,2 Journal of Allergy
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Figure 1: Layers forming the protective epidermal barrier.
and stratum basale. The structure of these layers is demon-
strated in Figure 1 [9]. Until recently, the outermost layer of
the dermis was relatively ignored as a factor in the develop-
mentofatopicdermatitis.Intheepidermistherearemultiple
components important to barrier function. These com-
ponents include claudin, desmoglein, ﬁlaggrin, ceramide,
and proper control of proteases (Table 1). When properly
functioning, this layer prevents water loss and provides a
barrier to epidermal invasion of allergens and bacteria.
Each corneocyte in the stratum corneum is held together
by tight junctions and scaﬀolding proteins. Claudins are a
family of proteins that are important components of the
tight junctions between corneocytes that help to maintain
the skin barrier. Claudin-deﬁcient patients have aberrant
formation of tight junctions that cause disruption of the
bioelectric barrier [10]. Claudins are an essential component
controlling the paracellular barrier ﬂow of molecules in the
intercellular space between the cells of an epithelium. These
tight junctions help prevent moisture loss through this layer
of the skin as well as block access through the skin of external
environmental allergens. Claudin expression in atopic der-
matitis patients has been inversely correlated to increased
TH2 biomarker expression [10]. This suggests that claudin
may help inhibit immune exposure to allergic stimuli.
Similar tight junction dysfunction has been found in
desmoglein transgenic mice. Desmogleins play a role in
theformationofdesmosomesthatpromotescell-to-celltight
junction adhesion in the stratum corneum. Mice without
desmoglein were ultimately found to die from dehydration
presumably due to increased transepidermal water loss
mediated by lack of corneocyte adhesion [11].
Ad i ﬀerent genetic knock-out mouse model of atopic
dermatitis examined the relationship between scaﬀolding
proteins and skin barrier function. Scaﬀolding proteins are
required to overlaying tight junction linked corneocytes
with cross-linked proteins and lipids to form an eﬀective
epidermal barrier. Loss of epidermal scaﬀolding proteins
such as involucrin, envoplakin, and periplakin is associated
with alterations in epidermal barrier function such as
ﬁlaggrin and desmoglein-1 processing with formation of an
abnormal corniﬁed epidermal envelope [12]. Immune reg-
ulatory dysfunction after disruption of scaﬀolding proteins
was associated with increased CD4+T cell inﬁltration and
lack of gamma delta+ T cells. This association suggests that
an abnormal epidermal layer may contribute to the allergic
inﬂammatory process associated with atopic dermatitis.
Anotherfactorallowingproperfunctionoftheepidermis
is the control of the on or oﬀ activity of skin proteases.
SPINK is a protein that inhibits serine protease action in the
skin. The SPINK gene is absent in Netherton’s syndrome.
This syndrome is characterized by severe atopic dermatitis,
scaling, and an elevated serum IgE [13]. In this potentiallyJournal of Allergy 3
Table 1: Functions of epidermal barrier components and possible protective role in prevention of atopic march.
Barrier component Type Function Possible role in preventing
atopic march
Claudin Tight junction protein Prevention of water loss Prevention of TH2
activation
Desmoglein Desmosome formation Prevention of water loss Blocking allergen
penetration
Involucrin/envoplakin/periplakin Scaﬀolding protein Structural components to
create epidermal barrier
Allowing appropriate
immunoregulatory T-cell
environment
Urocanic acid Chromophore Hygroscopic acid-base
regulator/photoprotection
Maintaining skin barrier
function
Filaggrin Protein
Decreased permeability of
water soluble
molecules/epidermal
diﬀerentiation
Blocking allergen
penetration
Ceramide Lipid
Contribution to skin
permeability barrier and
epidermal diﬀerentiation
Blocking mast cell
inﬁltration/expression of
TNF
Blocking Mast production
of allergic cytokines.
Blocking allergen
penetration
Skin protease inhibitors (SPINK) Protein
Prevention of protease
alteration in ﬁlaggrin and
ceramide production
Maintaining skin barrier
function
lethal disease, lack of SPINK results in uncontrolled serine
protease elastase-2 activity. Increased protease activity nega-
tively alters ﬁlaggrin and lipid (ceramide) processing thereby
decreasing skin barrier function. It has been suggested that
barrier function in populations with SNP alterations of
SPINK5 may lead to increased susceptibility to asthma [14].
Increased protease functioning also occurs in atopic
dermatitis patients. Allergens such as dust mite, cockroach
and mold can activate serine proteases, adversely aﬀecting
the epidermal barrier [15]. In fact, dust mite and cockroach
allergens themselves can be proteolytically active and stim-
ulate the serine protease pathway thereby decreasing skin
barrier function [16, 17].
Filaggrin is an important protein found in lamellar
bodies of stratum granulosum corneocytes. When these
granules are released they become a vital component of
the extracellular matrix of the stratum corneum. Mutations
of the ﬁlaggrin gene have been associated with ichthyosis
vulgaris and persistent atopic dermatitis [18, 19]. Filaggrin
gene defects may exist in as many as 50% of atopic dermatitis
patients [20, 21]. Meta-analysis of ﬁlaggrin polymorphism
data has identiﬁed a genetic alteration in ﬁlaggrin as a
signiﬁcant risk for development of atopic dermatitis [22].
The results of ﬁlaggrin gene mutations are striking as
several studies have demonstrated that the severity of atopic
dermatitis correlates with the number of ﬁlaggrin gene
defects [23–26].
4.PermeabilityLayerDisruptionIs
BidirectionalAllowingBothEpidermalWater
Loss and Allergen Penetration.
The lipid lamellar matrix is an integral component in
controlling the barrier function of the skin. Decreased
protein-bound omega-hydroxyceramides are found in the
lesional skin of atopic dermatitis patients as compared to
control patients [27]. In this study, deﬁciency of barrier lipid
free ceramides was determined to be a major contributing
factor in damaging the permeability barrier of the skin.
A murine model of atopic dermatitis illustrates the im-
portance of ceramide in preventing allergen-induced atopic
dermatitis. In this model, a synthetic ceramide was applied
to the skin of mice noted for the ability to develop atopic
dermatitis [28]. In this model of dust-mite-induced atopic
dermatitis, ceramide application reduced skin thickness
and actually blocked components of allergic inﬂammation.
Inﬂammatory factors prevented were the cutaneous inﬁltra-
tionbymastcellsandexpressionoftumornecrosisfactor.An
in vitro study has demonstrated that ceramide inhibits mast
cell production of IL-5, IL-10, and IL-13 [29]. These models
suggest that an intact lipid matrix in the strateum corneum
may actually prevent epidermal penetration of allergen and
allergic atopic dermatitis.
Filaggrin is another key protein in protecting against
water loss through the strateum corneum and is present in4 Journal of Allergy
the epidermis as early as 3 months of age [30]. Filaggrin-
deﬁcient atopic dermatitis patients have decreased ﬁlaggrin-
derived natural moisturization factors [31, 32]. The function
of ﬁlaggrin in the development of the epidermal barrier
has been conﬁrmed in murine models of atopic dermatitis.
Scharschmidt et al. describe altered lamellar body secretion
in an atopic dermatitis ﬂaky tailed mouse model. In this
model, a decrease in stratum corneum extracellular matrix
component correlated with increased permeability of water
soluble molecules [33].
D e g r a d a t i o np r o d u c t so fﬁ l a g g r i nh a v eb e e nf o u n dt o
contribute to the formation of the epidermal barrier by
providing acidity. This critical function of acidiﬁcation and
hydration of the skin has been linked to ﬁlaggrin gene
defects in atopic dermatitis [34]. In vitro models of skin
demonstrate that urocanic acid is a key ﬁlaggrin-derived
amino acid linked to skin acidity [35]. In this study, skin
pH became more basic with decreased ﬁlaggrin, which was
associated with an increase in dye penetration. The skin
performsavitalfunctioninprovidingbarrierfunction,andif
this is interrupted by ﬁlaggrin deﬁciency, then inﬂammatory
irritants, haptens, and infections have greater access to the
deeper layers of the skin.
5.BarrierProteinsMay Be One Lineof
Defense againstAllergicDiseases
In studies of ﬁlaggrin-deﬁcient children, increased transepi-
dermal water loss along with development of speciﬁc IgE
antibody to dust mite and cat was found with asthma
[36, 37]. A recent meta-analysis conﬁrmed that the risk
of developing asthma was increased in those with eczema
but not in those without atopic dermatitis. Filaggrin gene
mutations were linked directly to atopic dermatitis, allergic
rhinitis, and the development of asthma in children [38,
39]. These studies together suggest that the lack of barrier
function itself may contribute to the development of allergy
and asthma.
This reduction in barrier function may allow for the
development of inﬂammation due to increased penetration
of allergen through the skin allowing IgE sensitization. In
a ﬁlaggrin-deﬁcient murine model, allergen exposure over
lesional skin was linked to the development of allergen-
speciﬁc IgE and Th17 expression [40]. Facilitation of aller-
gen sensitization in individuals with ﬁlaggrin deﬁciency
is believed to be due to reduced barrier function. This
hypothesis of increased skin penetrability correlating with
diminished barrier function has been tested with both water
and lipid soluble dyes in vivo. Dye penetration was deepest
withseverityofatopicdermatitisandcorrelatedtoincreasing
serum IgE as compared to control patients [34, 35].
6.The Atopic March
Children with atopic dermatitis have a signiﬁcant risk of
going on to develop other atopic diseases such as allergic
sensitization and asthma. Whether eczema precedes or post-
dates the development of allergic sensitization is not clear for
all children [41]. Thirty to ﬁfty percent of the children who
develop atopic dermatitis go on to develop asthma and two-
thirds go on to have allergic rhinitis [36, 42]. In one study
of 169 infants with eczema, 35% developed subspecialist-
diagnosed asthma and these children had inhalant-induced
allergy [36].
The allergic march has a pattern of allergic sensitization
that changes as children age. In a study with 262 children
withatopicdermatitis,IgEsensitizationtofoodwascommon
under2yearsofage.Between2and5yearsofagethechildren
had food allergy but also started to develop inhalant allergy.
After 5 years of age the children had mostly inhalant allergy
as a signiﬁcant allergic factor associated with their atopic
dermatitis [43].
Dust mite and cockroach are allergens associated with
atopic dermatitis [44]. Alternaria allergy eventually develops
in 56% of atopic dermatitis children by 12 years of age [45].
When 30 children with atopic dermatitis were compared
with 30 patients with respiratory symptoms without atopic
dermatitis, aeroallergen allergy was signiﬁcant in a selected
population of atopic dermatitis patients. Of these children
with atopic dermatitis, 70% were skin test positive for mite,
70% were positive for cockroach, 63% were skin test positive
to house dust, 50% had evidence of IgE sensitization to
mold, and 43% had IgE reactivity to grass. However, only
10 percent of the kids with respiratory symptoms (and no
atopic dermatitis) were allergic to any aeroallergen in this
study [46]. This suggests an important link between atopic
dermatitis and development of inhalant allergy rather than
inhalation of allergen resulting in allergic sensitization and
asthma.
Studies suggest that a signiﬁcant number of these
children develop atopic dermatitis ﬁrst and subsequently
become sensitized to aeroallergens. Allergic rhinitis and
asthma then follow. Suggested risk factors for this chain
of events include atopic parents, possibly cat ownership
[47] ,a n dp r e s e n c eo fe c z e m ap r i o rt o4y e a r so fa g e
[48]. The progression to asthma is as high as 29.5% in
children with eczema [49]. Cumulative smoke exposure may
be an additional risk factor inﬂuencing the development
of asthma in FLG-null patients [50]. A recent genome-
wide study found that FLG mutation was associated with
a chromosomal (11q13.5) variant. These individuals had
increasedriskofdevelopingatopicdermatitisassociatedwith
asthma [51]. This risk of atopic dermatitis patients then
developing asthma is signiﬁcant enough that the Asthma
Predictive Index utilizes the presence of atopic dermatitis in
a wheezing infant as one of two major criteria for predicting
eventual asthma [52].
7. Therapeutic Options InvolvingBarrier
FunctionandAtopicDermatitis
Identiﬁcation of ceramide as a critical element in barrier
function has led to the development of ceramide-based
emollients. In a study of mild-moderate atopic dermatitis
patients, application of ceramide emollient resulted in
69% of patients having no symptoms of eczema and skinJournal of Allergy 5
hydrations scores improving signiﬁcantly [53]. Ceramide-
dominant lipid-based emollient was used in 24 children
with stubborn atopic dermatitis. In this study, skin cohesion
and transepidermal water loss levels improved with atopic
dermatitis scores as a result of the reestablishment of
extracellular lamellar membranes in the stratum corneum
[54]. As in murine studies, ceramide-based emollients in
humans have been shown to decrease inﬂammatory cytokine
interleukin-4 expression and decrease transepidermal water
loss in atopic dermatitis patients [55].
Strategies for possible prevention of atopic dermatitis
include encouraging the natural acidiﬁcation of the skin.
Treating mice with lactobionic acid was associated with
normal barrier function in addition to normalization of
atopic inﬂammatory markers such as serum IgE [56].
These atopic dermatitis mice achieved normal lamellar body
secretion and lipid bilayer formation after lactobionic acid
treatment only. In human patients, early studies suggest that
n e u t r a lp Hs o a p sm a yb ea ne ﬀective therapeutic component
when treating atopic dermatitis [57]. Whether neutral “baby
washes” or water washing alone after birth protects the
epidermal barrier and prevents the onset of atopic dermatitis
remains to be studied.
Immediate barrier repair can even be implemented on a
delipidizedstratumcorneumwithpetrolatumwithoutappli-
cation of ceramide [58]. A preliminary study investigated
whether petrolatum can be used immediately after birth
to prevent atopic dermatitis. High-risk neonates with ﬁrst-
degree relatives having atopic dermatitis or asthma were
enrolled at birth in a feasibility of prevention study [59]. The
study utilized an emollient cream and rescue petrolatum at
birth as a prevention of atopic dermatitis. This population
historicallyhasa30–50%riskofdevelopingatopicdermatitis
by2yearsofage.Only15%ofthesetreatedinfantsdeveloped
eczema and barrier function measurements reﬂective of
normal skin, which suggests a protective eﬀect.
8. Questions for the Future
Murine models suggest that allergen penetration through
the skin barrier is important to the development of atopic
dermatitis. Human studies show a link between barrier
protein dysfunction and development of atopic dermatitis
and possibly asthma. Clinical trials have not yet directly
looked at allergen penetration through a disordered skin
barrier and subsequent development of asthma. Controlled
trials with a signiﬁcant number of patients would be
important in determining whether prevention strategies
for decreasing allergic sensitization and atopic dermatitis
are eﬀective. Longer-term follow-up studies determining
whether the onset of allergic rhinitis and asthma is decreased
bydecreasingtheincidenceofeczemawouldalsobeexciting.
Itisapparentthatnotallpatientswithﬁlaggrindeﬁciency
go on to develop atopic dermatitis [60]. In fact, if they do
developeczema,remissionispossible.Ithasnotbeenstudied
whether these patients also are the same atopic dermatitis
patients who do not have disease progression to asthma.
Factors determining nonexpression of allergic rhinitis and
asthma have not been elucidated. Which populations are
destined to have a milder disease course? Patients may
“naturally” modify disease expression such as self-treatment
with hydration and if they do can it be applied as prevention
inhigh-risk infants?Whichgeneticmodiﬁers associatedwith
ﬁlaggrin deﬁciency lead to or prevent the atopic march?
Research in the alteration and prevention of loss of
stratum corneum barrier function may provide answers to
questions raised regarding the development of atopic der-
matitisandasthma. Earlyidentiﬁcationofat-riskindividuals
and developing treatment strategies allowing retention of
good skin barrier function may assist in the prevention of
allergic sensitization in some individuals. The atopic march
may not be inevitable for certain genetically predisposed
individuals.Researchintomaintenanceofbarrierfunctionin
patients at risk for atopy may elucidate the ability to control
skin barrier function and prevent onset of atopic dermatitis,
and, hopefully, asthma.
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